Federal Contractor Profile
Mapp Biopharmaceutical, INC.
$609M obligated·21 awards·2 agencies·7 NAICS
Federal Contracts
Showing award actions 1–50 of 78 funded award actions, most recent first.
- Contracts with positive obligations
- 21
- Funded award actions shown
- 78
- Obligations shown
- $609M
- Awarding agencies
- 2
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of September 30, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Sep 18, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00061 | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $322K |
| Sep 14, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00076 | 541714 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | $44M |
| Aug 12, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50124C00003 | 541714 | DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS | $2.6M |
| Jul 27, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00061 | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $33M |
| Jul 8, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00061 | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $3.2M |
| Jul 1, 2026 | Department of DefenseDEFENSE HEALTH AGENCY | HT942626FE075 | 325413 | PROCUREMENT OF HUMAN DERIVED MONOCLONAL ANTIBODIES AND RECOMBINANT ANTIGENS | $10K |
| Feb 6, 2026 | Department of DefenseDEFENSE HEALTH AGENCY | HT942626FE011 | 325413 | PROCUREMENT OF HUMAN DERIVED MONOCLONAL ANTIBODIES AND ANTIGENS | $21K |
| Sep 16, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942525FE048 | 325413 | HUMAN-DERIVED MONOCLONAL ANTIBODIES AND RECOMBINANT ANTIGENS | $61K |
| Jul 11, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00061 | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $50M |
| Jun 5, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942525F0237 | 325413 | ANTIBODY & ANTIGEN SUPPLY | $111K |
| May 28, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50124C00003 | 541714 | DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS | $43K |
| Jun 24, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00198 | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $109K |
| Mar 19, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50124C00003 | 541714 | DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS | $3.0M |
| Sep 22, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00061 | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $8.6M |
| Aug 7, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00076 | 541714 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | $13M |
| Jun 29, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00198 | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $718K |
| May 3, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00198 | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $1.5M |
| Apr 19, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00076 | 541714 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | $20M |
| Mar 1, 2023 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH21C0121 | 541380 | BASE YEAR FOR MACV CONTRACT GENERATES MACV IGG2 | $298K |
| Dec 22, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00061 | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $17M |
| Dec 7, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00024 | 541715 | IGF::OT::IGF | $868K |
| Dec 5, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119D00018 | 541714 | MAPP 2019 CONTRACT | $720K |
| Sep 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00076 | 541714 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | $78M |
| Sep 27, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122C00061 | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $110M |
| Sep 21, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600021C | 541720 | MAPP EAP - IGF::CL::IGF FOR OTHER FUNCTIONSEXPANDED ACCESS PROTOCOL FOR ZMAPP | $2.4M |
| Aug 15, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00198 | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $4.5M |
| Jun 22, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201700023C | 541711 | IGF::OT::IGF | $182K |
| Jun 2, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00198 | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $4.7M |
| Apr 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00024 | 541715 | IGF::OT::IGF | $917K |
| Jan 20, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00024 | 541715 | IGF::OT::IGF | $15M |
| Jan 20, 2022 | Department of DefenseW6QK ACC-APG | W911QY20C0099 | 541714 | STTR PHASE II | $500K |
| Jan 18, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600021C | 541720 | MAPP EAP - IGF::CL::IGF FOR OTHER FUNCTIONSEXPANDED ACCESS PROTOCOL FOR ZMAPP | $915K |
| Jan 10, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119D00018 | 541714 | MAPP 2019 CONTRACT | $7.3M |
| Dec 27, 2021 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH21C0121 | 541380 | BASE YEAR FOR MACV CONTRACT GENERATES MACV IGG2 | $89K |
| Dec 6, 2021 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA113C0018 | 541711 | BASE YEAR | $13K |
| Sep 24, 2021 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH21C0121 | 541380 | BASE YEAR FOR MACV CONTRACT GENERATES MACV IGG2 | $314K |
| Sep 9, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00198 | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $444K |
| Sep 1, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00024 | 541715 | IGF::OT::IGF | $970K |
| Jul 22, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201700023C | 541711 | IGF::OT::IGF | $453K |
| Apr 28, 2021 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0099 | 541714 | STTR PHASE II | $500K |
| Dec 10, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00024 | 541715 | IGF::OT::IGF | $4.8M |
| Dec 2, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119D00018 | 541714 | MAPP 2019 CONTRACT | $13M |
| Sep 28, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50120C00198 | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $4.5M |
| Aug 5, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0099 | 541714 | STTR PHASE II | $500K |
| Dec 31, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118C00024 | 541715 | IGF::OT::IGF | $20M |
| Sep 12, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201700023C | 541711 | IGF::OT::IGF | $39K |
| Aug 21, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201400009C | 541711 | IGF::CL::IGF FOR OTHER FUNCTIONS ADVANCED DEVELOPMENT OF ZMAPP, AN EBOLA VIRUS CANDIDATE MEDICAL COUNTERMEASURE | $567K |
| Jun 3, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119D00018 | 541714 | MAPP 2019 CONTRACT | $17M |
| May 16, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600021C | 541720 | MAPP EAP - IGF::CL::IGF FOR OTHER FUNCTIONSEXPANDED ACCESS PROTOCOL FOR ZMAPP | $8.6M |
| Apr 5, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201400009C | 541711 | IGF::CL::IGF FOR OTHER FUNCTIONS ADVANCED DEVELOPMENT OF ZMAPP, AN EBOLA VIRUS CANDIDATE MEDICAL COUNTERMEASURE | $147K |
Get Alerted Before Mapp Biopharmaceutical, INC.'s Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free